Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies

BACKGROUND: Immune checkpoint blockade (ICB) has achieved unprecedented success in treating multiple cancer types. However, clinical benefit remains modest for most patients with solid malignancies due to primary or acquired resistance. Tumor-intrinsic loss of major histocompatibility complex class...

Descripción completa

Detalles Bibliográficos
Autores principales: Minnar, Christine M, Chariou, Paul L, Horn, Lucas A, Hicks, Kristin C, Palena, Claudia, Schlom, Jeffrey, Gameiro, Sofia R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240938/
https://www.ncbi.nlm.nih.gov/pubmed/35764364
http://dx.doi.org/10.1136/jitc-2022-004561

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240938/
https://www.ncbi.nlm.nih.gov/pubmed/35764364
http://dx.doi.org/10.1136/jitc-2022-004561

Ejemplares similares